Back to today’s briefing

Story perspectives

Bristol Myers Squibb Stock: Undervalued at 8.63x Earnings

12/6/2025

50 9 Full Breakdown

Summary

Story summary

Bristol Myers Squibb (BMY) trades at 8.63x forward earnings, suggesting undervaluation relative to peers.
The stock's forward P/E is below its historical mean of 8.39x.
It is also below the large-cap pharma industry average of 16.95x.
Bristol Myers Squibb holds a Zacks Rank of #3 (Hold), indicating a neutral analyst outlook.

1 of 1

Story summary

Bristol Myers Squibb (BMY) trades at 8.63x forward earnings, suggesting undervaluation relative to peers.
The stock's forward P/E is below its historical mean of 8.39x.
It is also below the large-cap pharma industry average of 16.95x.
Bristol Myers Squibb holds a Zacks Rank of #3 (Hold), indicating a neutral analyst outlook.